| Date Filed | Type | Description |
| 08/23/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 05/19/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/10/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/15/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/15/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/10/2023 |
5
| Detheux Michel (CEO) has filed a Form 5 on iTeos Therapeutics, Inc. |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G
| VANGUARD GROUP INC reports a 5.1% stake in iTeos Therapeutics Inc. |
| 02/03/2023 |
8-K
| Quarterly results |
| 01/09/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/10/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/08/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 06/13/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/11/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 05/02/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/25/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/25/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/23/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/23/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 02/14/2022 |
SC 13G/A
| RTW INVESTMENTS, LP reports a 6.7% stake in iTeos Therapeutics, Inc. |
| 02/10/2022 |
SC 13G/A
| JANUS HENDERSON GROUP PLC reports a 0% stake in iTeos Therapeutics, Inc. |
| 01/11/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 12/09/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 11/10/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 10/19/2021 |
SC 13D/A
| MPM BioVentures 2014, L.P. reports a 14.6% stake in iTeos Therapeutics, Inc. |
| 09/21/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
|